Trial Profile
A Prospective, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of OTX-TIC (Travoprost) Implant in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Feb 2023
Price :
$35
*
At a glance
- Drugs Travoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Ocular Therapeutix
- 08 Feb 2023 Status changed from active, no longer recruiting to completed.
- 07 Nov 2022 According to an Ocular Therapeutix media release, topline data expected in Q4 of 2023.
- 11 Feb 2022 According to an Ocular Therapeutix media release, data from this trial will be presented at the Glaucoma 360 Meeting, 2022.